BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33045023)

  • 1. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.
    Jo H; Park Y; Kim J; Kwon H; Kim T; Lee J; Pyun JC; Lee M; Yun M
    PLoS One; 2020; 15(10):e0240107. PubMed ID: 33045023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 3. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
    Li SC; Martijn C; Cui T; Essaghir A; Luque RM; Demoulin JB; Castaño JP; Öberg K; Giandomenico V
    PLoS One; 2012; 7(10):e48411. PubMed ID: 23119007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
    Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
    Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.
    Froidevaux S; Hintermann E; Török M; Mäcke HR; Beglinger C; Eberle AN
    Cancer Res; 1999 Aug; 59(15):3652-7. PubMed ID: 10446977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.
    Wang S; Bao Z; Liang QM; Long JW; Xiao ZS; Jiang ZJ; Liu B; Yang J; Long ZX
    Hepatogastroenterology; 2013 Oct; 60(127):1639-46. PubMed ID: 24634935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.
    Fisher WE; Muscarella P; O'Dorisio TM; O'Dorisio MS; Kim JA; Doran TA; Sabourin CL; Schirmer WJ
    Surgery; 1996 Aug; 120(2):234-40; discussion 240-1. PubMed ID: 8751588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
    Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
    Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GIPR expression in gastric and duodenal neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways.
    Zou Y; Xiao X; Li Y; Zhou T
    Oncol Rep; 2009 Feb; 21(2):379-86. PubMed ID: 19148511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.
    Martinez-Alonso M; Llecha N; Mayorga ME; Sorolla A; Dolcet X; Sanmartin V; Abal L; Casanova JM; Baradad M; Yeramian A; Egido R; Puig S; Vilella R; Matias-Guiu X; Marti RM
    J Int Med Res; 2009; 37(6):1813-22. PubMed ID: 20146879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
    Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
    Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.